Skip Navigation


JAC Advance Access originally published online on December 12, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/1/93    most recent
dkg046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lin, C.-C.
Right arrow Articles by Lau, J. Y. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.-C.
Right arrow Articles by Lau, J. Y. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 93-99
© 2003 The British Society for Antimicrobial Chemotherapy

Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and Cynomolgus monkeys

Chin-Chung Lin*, Trong Luu, David Lourenco, Li-Tain Yeh and Johnson Y. N. Lau

Research and Development, Ribapharm, Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626, USA

Received 7 February 2002; returned 2 July 2002; revised 31 July 2002; accepted 20 August 2002

The absorption, pharmacokinetics and excretion of levovirin were studied in Sprague–Dawley rats (30 mg/kg) and Beagle dogs (30 mg/kg) following intravenous (iv) and oral administration of [3H]levovirin, and in Cynomolgus monkeys following iv and oral administration of [14C]levovirin. Oral absorption was 31.3% in rats, 67.3% in dogs and 17.5% in monkeys, and the bioavailability was 29.3% in rats, 51.3% in dogs and 18.4% in monkeys. After iv administration, the elimination half-life (t1/2) was 1.47 h in rats, 3.70 h in dogs and 3.50 h in monkeys. The total body clearance was 8.24, 2.96 and 2.58 mL/min per kg, respectively, in rats, dogs and monkeys and the apparent volume of distribution was 0.79, 0.95 and 0.65 L/kg. No metabolite was detected in plasma or urine of rats, dogs or monkeys, indicating negligible metabolism of levovirin in these animals. Excretion of total radioactivity in urine after oral dosing accounted for 15.4% of the administered dose in rats, 49.9% in dogs and 21.4% in monkeys. Biliary excretion did not play a significant role in the elimination of levovirin.

Keywords: levovirin, hepatitis C, metabolism, pharmacokinetics

* Corresponding author. Tel: +1-714-427-6236, ext. 2062; Fax: +1-714-641-7201; E-mail: cclin{at}ribapharm.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
M. Michaelis, R. Michaelis, T. Suhan, H. Schmidt, A. Mohamed, H. W. Doerr, and J. Cinatl Jr.
Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion
FASEB J, January 1, 2007; 21(1): 81 - 87.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y. Huang, S. Ostrowitzki, G. Hill, M. Navarro, N. Berger, P. Kopeck, C. I. Mau, T. Alfredson, and R. Lal
Single- and Multiple-Dose Pharmacokinetics of Levovirin Valinate Hydrochloride (R1518) in Healthy Volunteers
J. Clin. Pharmacol., May 1, 2005; 45(5): 578 - 588.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.